Review





Similar Products

recombinant ck7 antibody / cytokeratin 7  (NSJ Bioreagents)
96
NSJ Bioreagents recombinant ck7 antibody / cytokeratin 7
Recombinant Ck7 Antibody / Cytokeratin 7, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/Recombinant+CK7+Antibody+%2F+Cytokeratin+7/custom%40r20301%4041916182
Average 96 stars, based on 1 article reviews
recombinant ck7 antibody / cytokeratin 7 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
origene technologies ck7  (OriGene)
94
OriGene origene technologies ck7
Origene Technologies Ck7, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/Cytokeratin+7+(KRT7)+(NM_005556)+Human+Tagged+ORF+Clone/10__3892_slash_ol__2026__15695-75-34-34
Average 94 stars, based on 1 article reviews
origene technologies ck7 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
mouse monoclonal anti ck7  (Nichirei Biosciences)
86
Nichirei Biosciences mouse monoclonal anti ck7
Mouse Monoclonal Anti Ck7, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/67+anti+ki/pmc13034107-58-0-17
Average 86 stars, based on 1 article reviews
mouse monoclonal anti ck7 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
ck7  (Galectin Therapeutics)
86
Galectin Therapeutics ck7
Ck7, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/ck7/pmc13149142-15-8-12
Average 86 stars, based on 1 article reviews
ck7 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
ck7  (Huabio Inc)
86
Huabio Inc ck7
Ck7, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/antibody+ck7+primary/pm41877597-130-28-30
Average 86 stars, based on 1 article reviews
ck7 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
ck7  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology ck7
Ck7, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/Sox-2+Antibody/pm41877597-142-20-23
Average 96 stars, based on 1 article reviews
ck7 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti ck7  (Nichirei Biosciences)
86
Nichirei Biosciences anti ck7
Anti Ck7, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/anti+p40/pm41918815-68-2-17
Average 86 stars, based on 1 article reviews
anti ck7 - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
ck7  (OriGene)
94
OriGene ck7
Histopathological and immunohistochemical features of atypical eosinophilic renal cell tumours. A1–A6: Renal oncocytoma. A1: The tumour is well-circumscribed from the surrounding tissue and unencapsulated. A2: The tumour exhibits solid and nested/sheet-like growth with intervening edematous stroma. A3: <t>CK7</t> demonstrates focal strong cytoplasmic positive. A4: CD117 shows diffuse weak cytoplasmic positive. A5: CK20 is negative. A6: Colloidal iron staining is negative. B1–B6: Eosinophilic chromophobe renal cell carcinoma. B1: The tumour is relatively well-circumscribed, without involvement of the renal sinus fat. B2: Solidly packed tumour cells include distinct populations with botryoid morphology and eosinophilic cytoplasm. B3: CK7 shows diffuse strong cytoplasmic positive. B4: CD117 shows diffuse strong cytoplasmic positive. B5: CK20 is negative. B6: Colloidal iron staining is positive. C1–C6: Low-grade oncocytic tumour. C1: The tumour is well-circumscribed and unencapsulated. C2: Solid and acinar growth patterns are observed. C3: CK7 shows diffuse strong cytoplasmic positive. C4: CD117 is negative. C5: CK20 is negative. C6: Colloidal iron staining is negative. D1–D6: Eosinophilic vacuolated tumour. D1: The tumour is relatively well-circumscribed from the adjacent normal tissue, with scattered proliferative blood vessels within the tumour. D2: The tumour is arranged in solid nests and cords. D3: CK7 shows focal weak cytoplasmic positive. D4: CD117 shows diffuse moderate cytoplasmic positive. D5: CK20 is negative. D6: Colloidal iron staining is negative. E1–E6: Eosinophilic solid and cystic renal cell carcinoma. E1: The tumour is well-circumscribed, unencapsulated, and exhibits a cystic and solid structure. E2: The tumour shows cystic and solid growth patterns. E3: CK7 is negative. E4: CD117 is negative. E5: CK20 shows focal strong cytoplasmic positive. E6: Colloidal iron staining is negative. F1–F6: Normal renal tissue (Control). F1: Normal renal tissue, showing renal tubules, glomeruli, and thick-walled vessels. F2: Normal renal parenchyma. F3: CK7 shows diffuse strong cytoplasmic positive. F4: CD117 shows diffuse strong cytoplasmic positive. D5: CK20 is negative. F6: Colloidal iron staining is negative. Hematoxylin and eosin (H&E) staining x20 (A1-F1) and x40 (A2-F2). EnVision for CK7, CD117 and CK20 × 200. Colloidal iron staining x200
Ck7, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ck7/Cytokeratin+7+(KRT7)+Mouse+Monoclonal+Antibody/pmc13137485-91-7-9
Average 94 stars, based on 1 article reviews
ck7 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

Image Search Results


Histopathological and immunohistochemical features of atypical eosinophilic renal cell tumours. A1–A6: Renal oncocytoma. A1: The tumour is well-circumscribed from the surrounding tissue and unencapsulated. A2: The tumour exhibits solid and nested/sheet-like growth with intervening edematous stroma. A3: CK7 demonstrates focal strong cytoplasmic positive. A4: CD117 shows diffuse weak cytoplasmic positive. A5: CK20 is negative. A6: Colloidal iron staining is negative. B1–B6: Eosinophilic chromophobe renal cell carcinoma. B1: The tumour is relatively well-circumscribed, without involvement of the renal sinus fat. B2: Solidly packed tumour cells include distinct populations with botryoid morphology and eosinophilic cytoplasm. B3: CK7 shows diffuse strong cytoplasmic positive. B4: CD117 shows diffuse strong cytoplasmic positive. B5: CK20 is negative. B6: Colloidal iron staining is positive. C1–C6: Low-grade oncocytic tumour. C1: The tumour is well-circumscribed and unencapsulated. C2: Solid and acinar growth patterns are observed. C3: CK7 shows diffuse strong cytoplasmic positive. C4: CD117 is negative. C5: CK20 is negative. C6: Colloidal iron staining is negative. D1–D6: Eosinophilic vacuolated tumour. D1: The tumour is relatively well-circumscribed from the adjacent normal tissue, with scattered proliferative blood vessels within the tumour. D2: The tumour is arranged in solid nests and cords. D3: CK7 shows focal weak cytoplasmic positive. D4: CD117 shows diffuse moderate cytoplasmic positive. D5: CK20 is negative. D6: Colloidal iron staining is negative. E1–E6: Eosinophilic solid and cystic renal cell carcinoma. E1: The tumour is well-circumscribed, unencapsulated, and exhibits a cystic and solid structure. E2: The tumour shows cystic and solid growth patterns. E3: CK7 is negative. E4: CD117 is negative. E5: CK20 shows focal strong cytoplasmic positive. E6: Colloidal iron staining is negative. F1–F6: Normal renal tissue (Control). F1: Normal renal tissue, showing renal tubules, glomeruli, and thick-walled vessels. F2: Normal renal parenchyma. F3: CK7 shows diffuse strong cytoplasmic positive. F4: CD117 shows diffuse strong cytoplasmic positive. D5: CK20 is negative. F6: Colloidal iron staining is negative. Hematoxylin and eosin (H&E) staining x20 (A1-F1) and x40 (A2-F2). EnVision for CK7, CD117 and CK20 × 200. Colloidal iron staining x200

Journal: BMC Cancer

Article Title: Subtyping atypical eosinophilic renal cell tumours through integrated morphological, immunohistochemical, and mutational characters

doi: 10.1186/s12885-026-15870-1

Figure Lengend Snippet: Histopathological and immunohistochemical features of atypical eosinophilic renal cell tumours. A1–A6: Renal oncocytoma. A1: The tumour is well-circumscribed from the surrounding tissue and unencapsulated. A2: The tumour exhibits solid and nested/sheet-like growth with intervening edematous stroma. A3: CK7 demonstrates focal strong cytoplasmic positive. A4: CD117 shows diffuse weak cytoplasmic positive. A5: CK20 is negative. A6: Colloidal iron staining is negative. B1–B6: Eosinophilic chromophobe renal cell carcinoma. B1: The tumour is relatively well-circumscribed, without involvement of the renal sinus fat. B2: Solidly packed tumour cells include distinct populations with botryoid morphology and eosinophilic cytoplasm. B3: CK7 shows diffuse strong cytoplasmic positive. B4: CD117 shows diffuse strong cytoplasmic positive. B5: CK20 is negative. B6: Colloidal iron staining is positive. C1–C6: Low-grade oncocytic tumour. C1: The tumour is well-circumscribed and unencapsulated. C2: Solid and acinar growth patterns are observed. C3: CK7 shows diffuse strong cytoplasmic positive. C4: CD117 is negative. C5: CK20 is negative. C6: Colloidal iron staining is negative. D1–D6: Eosinophilic vacuolated tumour. D1: The tumour is relatively well-circumscribed from the adjacent normal tissue, with scattered proliferative blood vessels within the tumour. D2: The tumour is arranged in solid nests and cords. D3: CK7 shows focal weak cytoplasmic positive. D4: CD117 shows diffuse moderate cytoplasmic positive. D5: CK20 is negative. D6: Colloidal iron staining is negative. E1–E6: Eosinophilic solid and cystic renal cell carcinoma. E1: The tumour is well-circumscribed, unencapsulated, and exhibits a cystic and solid structure. E2: The tumour shows cystic and solid growth patterns. E3: CK7 is negative. E4: CD117 is negative. E5: CK20 shows focal strong cytoplasmic positive. E6: Colloidal iron staining is negative. F1–F6: Normal renal tissue (Control). F1: Normal renal tissue, showing renal tubules, glomeruli, and thick-walled vessels. F2: Normal renal parenchyma. F3: CK7 shows diffuse strong cytoplasmic positive. F4: CD117 shows diffuse strong cytoplasmic positive. D5: CK20 is negative. F6: Colloidal iron staining is negative. Hematoxylin and eosin (H&E) staining x20 (A1-F1) and x40 (A2-F2). EnVision for CK7, CD117 and CK20 × 200. Colloidal iron staining x200

Article Snippet: The antibodies used in the study are CK7 (EP16, Origene, Wuxi, China), CK20 (EP23, Origene, Wuxi, China), CD117 (EP10, Origene, Wuxi, China), mTOR (ab109268, Abcam, Shanghai, China), Vimentin (UMAB159, Origene, Wuxi, China), CAIX(H-11, Origene, Wuxi, China), SDHB (OTI1H6, Origene, Wuxi, China), FH (OTI1F10, Origene, Wuxi, China), Cathepsin K (ab37259, Abcam, Shanghai, China) and Pax8 (OTI6H8, Origene, Wuxi, China).

Techniques: Immunohistochemical staining, Staining, Control